CALGARY, Alberta, April 7, 2015 /PRNewswire/ --
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX)
announces that it has received two China patent approvals covering
RVX-208. A composition of matter patent, China No. 2007 8
0052349.8 titled, "Compounds for the Prevention and Treatment of
Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No.
ZL 2009 8 0106586.7 titled, "Methods of Preparing Quinazolinone
Derivatives" was granted until June
2029.
"These two additional patents build upon the growing
intellectual property estate for our core asset, RVX-208. With our
Chinese patent life extending out to June
2029, RVX-208 now has the necessary protection required for
a regional licensing deal in China," stated Donald McCaffrey,
president and CEO of Resverlogix. Mr. McCaffrey added, "Resverlogix
views the ever expanding Chinese pharmaceutical market as an
attractive opportunity which aligns with our regional licensing
strategy. We will continue our discussions with potential partners
at the China Bio Partnering Forum in Shanghai next week." On April 15th, Resverlogix is one of four
selected Canadian companies who will be presenting at China
Bio.
About RVX-208
RVX-208 is a first-in-class, small molecule selective BET
bromodomain inhibitor. BET bromodomain inhibition is an epigenetic
mechanism that can turn disease-causing genes off, returning them
to a healthier state. RVX-208 is the first and only BET inhibitor
selective for BRD4-BD2, producing a nexus of biological effects
with potentially important benefits for patients with diseases such
as cardiovascular disease (CVD), diabetes mellitus (DM),
Alzheimer's disease, peripheral artery disease, and chronic kidney
disease while maintaining an excellent safety profile. Resverlogix
is planning to study RVX-208 in a proposed Phase 3 clinical trial
in CVD patients with DM and low HDL.
About Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small
molecule selective BET bromodomain inhibitor for the potential
treatment of patients with cardiovascular disease, diabetes
mellitus, Alzheimer's disease, peripheral artery disease, and
chronic kidney disease. RVX-208 is the only selective BET
bromodomain inhibitor in clinical trials. Resverlogix's common
shares trade on the Toronto Stock Exchange (TSX: RVX). For further
information please visit http://www.resverlogix.com. We can be
followed on our blog at http://www.resverlogix.com/blog and via
Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the
words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release
includes forward looking information relating to research and
development activities and the potential role of RVX-208 in the
treatment of cardiovascular disease, Alzheimer's
disease, peripheral artery disease and chronic kidney disease. Our
actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including those discussed in our Annual Information
Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR
at http://www.sedar.com. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
For further information, please
contact:
Company
Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email:
don@resverlogix.com
Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: +1-403-254-9252
Email: sarah@resverlogix.com
Media:
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1-212-845-4251
Phone: +1-212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com